'Big data' analysis links herpes virus to Alzheimer's by Amirah Al Idrus Thursday, June 21, 2018 A "multi-omic" analysis of more than 900 donor brains linked the amount of herpes virus in a person's brain to the presence of Alzheimer's markers.
Organ-chip developer Emulate raises $36M in VC funding by Conor Hale Tuesday, June 19, 2018 Organ-chip developer Emulate gathered $36 million in VC financing and plans to include a wider range of diseases in its models for drug testing.
Lilly, AstraZeneca can phase 3 Alzheimer’s trials by Nick Paul Taylor Tuesday, June 12, 2018 The partners stopped the two phase 3 studies after an independent interim analysis deemed they were destined to fail.
Advaxis cuts staff, seeks partner for troubled cancer vaccine by Phil Taylor Friday, June 8, 2018 Almost a quarter of Advaxis' workforce is facing the chop as it scales back trials of its lead cancer immunotherapy, currently on clinical hold.
Chutes & Ladders—Celgene's shake-ups continue by Conor Hale Friday, June 8, 2018 Celgene's shake-ups continue with new CFO, Zai Lab grabs top AZ exec, Axovant brings on Spark co-founder as CTO, and Gilead promotes its top dealmaker.
Pfizer’s dacomitinib bests Iressa in NSCLC OS showdown by Nick Paul Taylor Tuesday, June 5, 2018 The results of a phase 3 trial suggest dacomitinib is more effective than its aging rival.
Small molecule silences cancer-driving RNA by Amirah Al Idrus Friday, June 1, 2018 Scientists have developed a small molecule that can selectively target RNA and could pave the way for a pill that can treat genetic diseases.
AZ opens South San Francisco facility housing 400 R&D staff by Phil Taylor Wednesday, May 23, 2018 AstraZeneca has opened its new South San Francisco R&D facility, bundling five sites into a single unit at the heart of California’s biotech cluster.
AstraZeneca drops Amgen-partnered solid tumor drug by Nick Paul Taylor Friday, May 18, 2018 The CEA-CD3 bispecific T-cell engager was pitched as a treatment for colorectal cancer but looks to have failed in early-phase trials.
Restless R&D execs on the move to rival pharmas by Ben Adams Tuesday, April 24, 2018 Pharma R&D executives are jumping ships to rivals in droves this season.
